Supreme Court backs Trump administration termination of $783 million in NIH grants linked to DEI initiatives

22 August 2025

By a vote of 5-4, the US Supreme Court on Thursday agreed to allow the National Institutes of Health, the largest public funding source for biomedical research in the world, to terminate $783 million in grants linked to DEI initiatives.

In a brief unsigned order, the court granted a request from the Trump administration to pause a ruling by a federal judge in Massachusetts that required the federal government to continue making the payments. Also by a vote of 5-4, the court left in place a different portion of the judge’s ruling, which had thrown out internal NIH guidance documents describing the agency’s policy priorities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Pharmaceutical